N/A N=169 Intervention to Improve Adherence in Teen Kidney Transplant
Kidney Transplantation · Medication Adherence
Primary: Taking Adherence — 78; 68 % of days with 100% taking adherence — p=0.006
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Chemoembolization Using Doxorubicin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
Liver Cancer
Primary: Safety — 16; 3 Participants
Phase 4 N=8 A Study to Determine if Caffeine Accelerates Emergence From Anesthesia
Anesthesia
Primary: Waking Time - Re-establishment of the Gag Reflex. — 16.45; 9.57 minutes — p=0.002
N/A N=44 Absorption and Safety With Sustained Use of RELiZORB Evaluation (ASSURE) Study
Cystic Fibrosis
Primary: Change From Baseline of Erythrocyte Omega-3 Index % (DHA+EPA) — 5.01 percentage of omega-3 composition
N/A N=396 A Clinical Study to Evaluate the Efficacy of Three Dry Mouth Relief Products Versus Water
Xerostomia
Primary: Modified Product Performance and Attributes Questionnaire I (PPAQ I) (Question Number 1: Relieving the Discomfort of Dry Mouth) — 2.7; 2.9; 2.6; 2.0 Score on scale…
Phase 2 N=45 A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
Symptomatic Focal Vitreomacular Adhesion
Primary: Release of Vitreo Macular Adhesion (VMA) by Optical Coherence Tomography (OCT) — 4; 0 Participants
Phase 2 N=14 Effects of Two Doses of MPX Capsules on Rising Prostate-specific Antigen Levels in Men Following Initial Therapy for Prostate Cancer
Prostate Cancer
Primary: (Phase I) Maximum Tolerated Dose — 4000 mg
N/A N=300 Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process
Chronic Fatigue Syndrome
Primary: Changes in Frequency and Severity of CDC-based CFS Symptoms — 0.29; 0.12; 0.49; 0.05 Units on a scale
Phase 2 N=3 Sutent and Radiation as Treatment for Limited Extent Metastatic Cancer
Cancer
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1; 2 Participants
Phase 2 N=112 Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma
Unresected Stage IIIb to IVM1c Melanoma
Primary: Odds Ratio of Baseline Intratumoral CD8+ Cell Density and Objective Response Rate — 1.11 ratio — p=0.387
Phase 2 N=17 Adoptive Transfer of Haplo-identical DLI for AML and MDS
Acute Myeloid Leukemia · Myelodysplastic Syndrome
Primary: Number of Subjects With Unacceptable Toxicity — 1 Participants
Phase 1 N=59 A Multiple Dose Study of LY2541546 in Healthy Postmenopausal Women
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 participants
Phase 3 N=63 Eosinophilic Esophagitis Intervention Trial-1 Food vs. 4 Food Elimination Diet Followed by Swallowed Glucocorticoids
Eosinophilic Esophagitis · Eosinophilic Gastrointestinal Disorders (EGIDs)
Primary: Change From Baseline in Pediatric EoE Symptom Score Version 2.0 (PEESS V2.0) at 12 Weeks — -14.3; -21.6 units on a scale — p=0.04
N/A N=163 The Asahi Intecc PTCA Chronic Total Occlusion Study
Coronary Artery Disease · Coronary Artery Chronic Total Occlusion
Primary: Procedure Success — 119 Participants
Phase 4 N=70 24-hour Mifepristone and Buccal Versus Mifepristone and Vaginal Misoprostol for Cervical Preparation for D&E
Abortion, Second Trimester
Primary: Procedure Time — 9.5; 9.9 minutes